Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9625482 | 0.88 | CHRM2 (0.63) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL469610 | 0.84 | CHRM2 (0.55) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL799700 | 0.83 | CHRM2 (0.58) | CHRM2DRD3ALDH1A1MEN1CYP1A2 | |
| SCHEMBL3727196 | 0.81 | CHRM2 (0.56) | CHRM2ALDH1A1 | |
| SCHEMBL5962347 | 0.80 | CHRM2 (0.54) | CHRM2ALDH1A1MEN1CYP1A2CYP2C19 | |
| SCHEMBL19228128 | 0.80 | CHRM2 (0.55) | CHRM2DRD3ALDH1A1 | |
| SCHEMBL4580822 | 0.79 | DRD3 (0.47) | CHRM2DRD3ALDH1A1MEN1CYP1A2 | |
| SCHEMBL14480981 | 0.79 | CHRM2 (0.54) | CHRM2ALDH1A1 | |
| SCHEMBL7260725 | 0.79 | CHRM2 (0.54) | CHRM2ALDH1A1 | |
| SCHEMBL14481161 | 0.79 | CHRM2 (0.54) | CHRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003209-B | Macrocyclic compounds as TRK kinase inhibitors | 阵列生物制药公司 | 2022-01-25 | — | — | CN | disclosed |
| US-20200291026-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2020-09-17 | — | — | US | disclosed |
| US-10647730-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3521291-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190031684-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-01-31 | — | — | US | disclosed |
| WO-2018114777-A1 | NITROGEN-CONTAINING BIOPOLYMER-BASED CATALYSTS, THEIR PREPARATION AND USES IN HYDROGENATION PROCESSES, REDUCTIVE DEHALOGENATION AND OXIDATION | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-28 | — | — | WO | disclosed |
| US-9902741-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9840519-B2 | Macrocyclic compounds as TRK kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170283435-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9750744-B2 | Macrocyclic compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2571883-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146336-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-5767121-A | ANTIINFLAMMATORY AND -ARTHRITIC AGENTS; ANTIPYRETICS; ANALGESICS; ADHESION PROTEIN EXPRESSION AND CYCLOXYGENASE AND 5-LIPOXYGENASE INHIBITORS; IMMUNOSUPPRESSANTS AND -MODULATORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-06-16 | — | — | US | disclosed |
| EP-0612729-B1 | Pyridine derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-04-23 | — | — | EP | disclosed |
| US-5561147-A | ANTIINFLAMMATORY AGENT, ANTIPYRETIC, ANALGESICS, ANTIALLERGENS, IMMUNOSUPPRESSANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-10-01 | — | — | US | disclosed |
| US-5457106-A | Antiinflammatory agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-10 | — | — | US | disclosed |
| US-5389658-A | Administering as antipyretic, antiinflammatory, analgesic, antiallergic, or immunosupressive agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0612729-A2 | Pyridine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1994-08-31 | — | — | EP | disclosed |
| US-5246948-A | Antiinflammatory, antipyretic, analgesic, antiallergic, immunosupressing or immunomodulating activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-21 | — | — | US | disclosed |
| EP-0522606-A2 | Pyridine derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291026-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | CHRM2 1627/4885DRD3 1073/4885ALDH1A1 4546/4885 |
| US-20190031684-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | CHRM2 1918/4885DRD3 2377/4885ALDH1A1 4492/4885 |
| US-20170283435-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K3 | CHRM2 1627/4885DRD3 1073/4885ALDH1A1 4546/4885 |
| US-10647730-B2 | Macrocyclic compounds as TRK kinase inhibitors | MAP3K20, MAP3K1, MAP3K3 | CHRM2 1918/4885DRD3 2377/4885ALDH1A1 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.